TP53 and prostate carcinoma: This study ascertained that CAPE can suppress MALT1 expression via upregulation of p53, anti-NF-κB, and antiandrogen activations, as well as attenuating the growth, proliferation, and invasion of prostate carcinoma cells both in vitro and in vivo.